Gvm Care Founder and CEO Ettore Sansavini Sees a Bright Technological Future in Healthcare

Photo of author

(Newswire.net — May 28, 2021) — In less than one year after the World Health Organisation declared the Covid-19 pandemic, laboratories in the United Kingdom, India, China, Russia, and Brazil were already working on new technologies applied to medicine during the development of a vaccine. As of March 2021, over 30 million British citizens have already received the first dose, and over 3 million are already fully immunized with the second dose. 

Such an achievement not only stresses the success of UK logistics and healthcare professionals but especially the ability to use research and technology to solve major issues: from a pandemic to long waits for organ transplantation and precise diagnosis and treatment of debilitating conditions such as cancer. With technology evolving at exponential rates, a quickly developed Covid-19 vaccine is just a glimpse of what the future holds, according to Ettore Sansavini.

As founder and CEO of GVM Care & Research, one of the main Italian groups active in private healthcare as well as one of the world leaders in the field of research and new technologies applied to medicine, Sansavini envisions a future of personalized medicine, gene therapy, nanomedicine, artificial intelligence, robotics, and big data applied to healthcare. “Advances in the healthcare sector are already a reality, especially on the side of surgical robots and more human-centric applications,” he argues. 

As a company, GVM Care & Research has always set itself the goal of constantly overcoming the frontiers of current technology, in search of new innovative methods and systems for clinical engineering and production process innovation. The introduction of the Da Vinci robot, Navio hybrid technology and Artis Zeego/Theno in operating rooms in the field of cardiovascular, bariatric, and urological surgery are just a few examples of the revolution that these technologies are prompting.

For Sansavini, the fact that the number of devices based on the model of communication and interaction machine-machine with humans has already reached 50 billion only proves that we have already entered the era of the internet of things. Hence, such an achievement offers the possibility to reach more people with quality healthcare information by using an omnichannel strategy that, complementary, will be also connected to the way hospitals and clinics address their customer services.

This is the case for Pepper Robot, the first humanoid companion robot capable of recognizing faces and main human emotions. First introduced by GVM Care & Research at the Hospital San Carlo di Nancy, the robot Pepper is constantly being optimized for human interaction, so that it can interact with people through conversations and a touch screen interface. After becoming a success in Japan, the robot is growing in the hearts of Europeans as it is introduced as a project to facilitate patient access to facilities. “More than 2,000 companies around the world have already adopted Pepper as an assistant to receive, inform and guide visitors in an innovative way,” tells Sansavini.

In terms of longevity and the rapidly aging of the population, the CEO of GVM Care & Research stresses that the advances in nanomedicine will undoubtedly bring benefits in the fight against debilitating diseases often associated with old age, such as cancer, cardiovascular diseases, Alzheimer’s, Parkinson’s and diabetes. “Nanomedicine will provide a personalized and targeted response with less economic impact and will have a positive impact on quality of life, thanks to the use of drugs that will only act on specific cells,” says Sansavini. 

Another revolution that the CEO of GVM Care & Research envisions is how, in the coming years, stem cell therapy will become increasingly popular thanks to the reproduction of organs in the laboratory. Such a development not only promises a reduction in the waiting for organ transplantation, but it actually works as an ultra-specialized solution that reduces the risk of rejection, and that will be an even greater development of traditional stem cell surgery. In other words, after the Covid-19 dark days, there are lots of bright, technological futures to expect according to Sansavini.